<p>Bio-Techne（納斯達克代碼：TECH - 獲取免費報告）在週四的報告中被 Leerink Partners 的股票分析師從 “強力買入” 評級下調至 “持有” 評級，Zacks.com 報道。</p>
<ul>
<li>Bio-Techne、J2 Global 和 InMode 突破底部，接近買入點</li>
</ul>
<p>其他分析師也對該股票發佈了報告。德意志銀行將 Bio-Techne 的股票評級從 “買入” 下調至 “持有”，並設定了 73.00 美元的目標價。在 6 月 8 日的研究報告中，Zacks Research 將 Bio-Techne 的評級從 “持有” 下調至 “強烈賣出”。William Blair 在週四的研究報告中將 Bio-Techne 的股票評級從 “跑贏大盤” 下調至 “市場表現”。Piper Sandler 在 6 月 11 日的報告中開始覆蓋 Bio-Techne 的股票，給予 “中性” 評級和 65.00 美元的目標價。最後，TD Cowen 在週二的研究報告中重申了 Bio-Techne 的 “買入” 評級。兩位投資分析師給予該股票 “強力買入” 評級，八位給予 “買入” 評級，六位給予 “持有” 評級，一位給予 “賣出” 評級。根據 MarketBeat.com 的數據，該公司的平均評級為 “適度買入”，共識目標價為 65.79 美元。</p>
<p><strong>查看我們最新的研究報告關於 TECH</strong></p>
<h2>Bio-Techne 股票表現</h2>
<p>週四，TECH 的股票開盤價為 70.70 美元。該公司的市值為 110.7 億美元，市盈率為 102.47，市盈增長比率為 5.67，貝塔值為 1.37。該公司的速動比率為 3.18，流動比率為 4.49，債務股本比率為 0.10。該公司的 50 日簡單移動平均為 52.70 美元，200 日簡單移動平均為 56.99 美元。Bio-Techne 的 52 周低點為 43.19 美元，52 周高點為 72.16 美元。</p>
<p>Bio-Techne（納斯達克代碼：TECH - 獲取免費報告）最後一次發佈財報是在 5 月 6 日，生物技術公司報告季度每股收益為 0.53 美元，低於分析師一致預期的 0.55 美元（差額為 0.02 美元）。Bio-Techne 的股本回報率為 13.57%，淨利潤率為 9.05%。該公司季度收入為 3.1142 億美元，而分析師預期為 3.1611 億美元。在去年同期，該公司每股收益為 0.56 美元。與去年同期相比，該公司的季度收入下降了 1.5%。股票研究分析師預測 Bio-Techne 在當前財年將發佈 1.66 美元的每股收益。</p>
<h2>對 Bio-Techne 的對沖基金看法</h2>
<p>幾家對沖基金和其他機構投資者最近買入和賣出了該股票的股份。NewEdge Advisors LLC 在第一季度將其在 Bio-Techne 的持倉增加了 15,993.8%。NewEdge Advisors LLC 目前擁有 7,725 股生物技術公司的股票，價值 404,000 美元，此前在上個季度增持了 7,677 股。Henshaw Capital LLC 在第一季度將其在 Bio-Techne 的股份增加了 31.2%。Henshaw Capital LLC 目前擁有 45,905 股生物技術公司的股票，價值 2,399,000 美元，此前在此期間增持了 10,915 股。Summitry LLC 在第一季度將其在 Bio-Techne 的持倉增加了 17.1%。Summitry LLC 目前擁有 6,013 股生物技術公司的股票，價值 314,000 美元，此前在上個季度增持了 879 股。Intrinsic Edge Capital Management LLC 在第一季度購買了 Bio-Techne 的新頭寸，價值約為 5,749,000 美元。最後，Edgestream Partners L.P.在第一季度購買了 Bio-Techne 的新頭寸，價值約為 292,000 美元。98.95% 的股票由機構投資者和對沖基金持有。</p>
<h2>影響 Bio-Techne 的關鍵頭條</h2>
<p>以下是本週影響 Bio-Techne 的關鍵新聞：</p>
<ul>
<li>積極情緒：默克 KGaA 同意以每股 73 美元的現金收購 Bio-Techne，為股東提供明確的退出價值，並可能推動股票接近交易價格。德國達姆施塔特的默克同意收購 Bio-Techne</li>
<li>積極情緒：該報價相對於 Bio-Techne 最近的股價具有相當大的溢價，通常會提升收購目標股票的價格，因為投資者會考慮交易完成。德國默克以每股 73 美元收購 Bio-Techne</li>
<li>中性情緒：多家律師事務所宣佈對股東進行調查，以確定 Bio-Techne 的董事會是否獲得了公平價格，這可能會產生法律噪音，但不會改變已宣佈的交易條款。股東警報：Ademi LLP 調查 Bio-Techne 公司是否為公眾股東獲得公平價格</li>
<li>中性情緒：報告的空頭頭寸數據顯示沒有顯著的空頭頭寸，因此這一舉動似乎更多是由收購公告驅動，而非空頭回補。Bio-Techne 因每股 73 美元的現金收購協議而激增</li>
</ul>
<h2>關於 Bio-Techne</h2>
<p>（獲取免費報告）</p>
<p>Bio-Techne Corporation（納斯達克：TECH）是一家全球生命科學公司，開發、製造和銷售高質量的試劑、儀器和服務，面向研究、診斷和生物加工市場。其核心產品包括重組蛋白、抗體、免疫測定、核酸探針和試劑盒、單細胞分析解決方案以及自動化蛋白分析系統。R&amp;D Systems、Novus Biologicals、ProteinSimple 和 Advanced Cell Diagnostics 等旗艦品牌為研究人員和臨牀醫生提供可靠的細胞生物學、免疫學、蛋白質組學和基因組學應用工具。</p>
<p>Bio-Techne 總部位於明尼阿波利斯，明尼蘇達州，通過直接銷售、分銷商和戰略合作伙伴關係為北美、歐洲和亞太地區的客户提供服務。</p>
<h2>推薦故事</h2>
<ul>
<li>我們更看好的五隻股票，而不是 Bio-Techne</li>
<li>黑莓的反彈不僅僅依賴於盈利，更是一個更大的人工智能故事</li>
<li>MDA Space 以 6.2 億美元收購目標美國國防市場</li>
<li>嘉年華的第二季度：這隻股票仍然複雜嗎？</li>
<li>多米諾的股票因投資者消化 CEO 更換而跌至 52 周低點</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VEVDSA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="650" height="330" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VEVDSA"/></p>
<p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資 1,000 美元在 Bio-Techne 嗎？</h2>
<p>在考慮 Bio-Techne 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄建議客户現在購買的股票，而 Bio-Techne 並不在名單上。</p>
<p>雖然 Bio-Techne 目前在分析師中獲得了中等買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

TECH

德國默克

<p>Leerink Partners 將 Bio-Techne（NASDAQ:TECH）的評級從 “強烈買入” 下調至 “持有”。其他分析師也調整了評級，德意志銀行和威廉·布萊爾將評級調整為 “持有”，Zacks 調整為 “強烈賣出”，而派珀·桑德勒則首次給予 “中性” 評級。TD Cowen 重申 “買入” 評級。該股票目前交易價格接近 70.70 美元，市場共識目標為 65.79 美元。默克集團同意以每股 73 美元的現金收購 Bio-Techne</p>

<p>Bio-Techne (NASDAQ:TECH - Get Free Report) was downgraded by stock analysts at Leerink Partners from a &#34;strong-buy&#34; rating to a &#34;hold&#34; rating in a report issued on Thursday,Zacks.com reports.</p>
<div class="lb-trans"><p>Bio-Techne（納斯達克代碼：TECH - 獲取免費報告）在週四的報告中被 Leerink Partners 的股票分析師從 “強力買入” 評級下調至 “持有” 評級，Zacks.com 報道。</p>
</div><ul>
<li>Bio-Techne, J2 Global And InMode Break Out Of Bases, Near Buy Points</li>
</ul>
<div class="lb-trans"><ul>
<li>Bio-Techne、J2 Global 和 InMode 突破底部，接近買入點</li>
</ul>
</div><p>Other analysts have also issued reports about the stock. Deutsche Bank Aktiengesellschaft lowered shares of Bio-Techne from a &#34;buy&#34; rating to a &#34;hold&#34; rating and set a $73.00 price target on the stock. in a research report on Friday. Zacks Research lowered Bio-Techne from a &#34;hold&#34; rating to a &#34;strong sell&#34; rating in a research note on Monday, June 8th. William Blair downgraded shares of Bio-Techne from an &#34;outperform&#34; rating to a &#34;market perform&#34; rating in a research note on Thursday. Piper Sandler initiated coverage on shares of Bio-Techne in a report on Thursday, June 11th. They issued a &#34;neutral&#34; rating and a $65.00 target price on the stock. Finally, TD Cowen reaffirmed a &#34;buy&#34; rating on shares of Bio-Techne in a research note on Tuesday. Two investment analysts have rated the stock with a Strong Buy rating, eight have assigned a Buy rating, six have given a Hold rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat.com, the company presently has an average rating of &#34;Moderate Buy&#34; and a consensus target price of $65.79.</p>
<div class="lb-trans"><p>其他分析師也對該股票發佈了報告。德意志銀行將 Bio-Techne 的股票評級從 “買入” 下調至 “持有”，並設定了 73.00 美元的目標價。在 6 月 8 日的研究報告中，Zacks Research 將 Bio-Techne 的評級從 “持有” 下調至 “強烈賣出”。William Blair 在週四的研究報告中將 Bio-Techne 的股票評級從 “跑贏大盤” 下調至 “市場表現”。Piper Sandler 在 6 月 11 日的報告中開始覆蓋 Bio-Techne 的股票，給予 “中性” 評級和 65.00 美元的目標價。最後，TD Cowen 在週二的研究報告中重申了 Bio-Techne 的 “買入” 評級。兩位投資分析師給予該股票 “強力買入” 評級，八位給予 “買入” 評級，六位給予 “持有” 評級，一位給予 “賣出” 評級。根據 MarketBeat.com 的數據，該公司的平均評級為 “適度買入”，共識目標價為 65.79 美元。</p>
</div><p><strong>View Our Latest Research Report on TECH</strong></p>
<div class="lb-trans"><p><strong>查看我們最新的研究報告關於 TECH</strong></p>
</div><h2>Bio-Techne Stock Performance</h2>
<div class="lb-trans"><h2>Bio-Techne 股票表現</h2>
</div><p>Shares of TECH opened at $70.70 on Thursday. The company has a market capitalization of $11.07 billion, a PE ratio of 102.47, a P/E/G ratio of 5.67 and a beta of 1.37. The company has a quick ratio of 3.18, a current ratio of 4.49 and a debt-to-equity ratio of 0.10. The company has a 50-day simple moving average of $52.70 and a 200-day simple moving average of $56.99. Bio-Techne has a 52-week low of $43.19 and a 52-week high of $72.16.</p>
<div class="lb-trans"><p>週四，TECH 的股票開盤價為 70.70 美元。該公司的市值為 110.7 億美元，市盈率為 102.47，市盈增長比率為 5.67，貝塔值為 1.37。該公司的速動比率為 3.18，流動比率為 4.49，債務股本比率為 0.10。該公司的 50 日簡單移動平均為 52.70 美元，200 日簡單移動平均為 56.99 美元。Bio-Techne 的 52 周低點為 43.19 美元，52 周高點為 72.16 美元。</p>
</div><p>Bio-Techne (NASDAQ:TECH - Get Free Report) last posted its earnings results on Wednesday, May 6th. The biotechnology company reported $0.53 EPS for the quarter, missing analysts' consensus estimates of $0.55 by ($0.02). Bio-Techne had a return on equity of 13.57% and a net margin of 9.05%.The firm had revenue of $311.42 million for the quarter, compared to analysts' expectations of $316.11 million. During the same quarter in the previous year, the firm posted $0.56 earnings per share. The firm's revenue for the quarter was down 1.5% compared to the same quarter last year. Equities research analysts predict that Bio-Techne will post 1.66 earnings per share for the current fiscal year.</p>
<div class="lb-trans"><p>Bio-Techne（納斯達克代碼：TECH - 獲取免費報告）最後一次發佈財報是在 5 月 6 日，生物技術公司報告季度每股收益為 0.53 美元，低於分析師一致預期的 0.55 美元（差額為 0.02 美元）。Bio-Techne 的股本回報率為 13.57%，淨利潤率為 9.05%。該公司季度收入為 3.1142 億美元，而分析師預期為 3.1611 億美元。在去年同期，該公司每股收益為 0.56 美元。與去年同期相比，該公司的季度收入下降了 1.5%。股票研究分析師預測 Bio-Techne 在當前財年將發佈 1.66 美元的每股收益。</p>
</div><h2>Hedge Funds Weigh In On Bio-Techne</h2>
<div class="lb-trans"><h2>對 Bio-Techne 的對沖基金看法</h2>
</div><p>Several hedge funds and other institutional investors have recently bought and sold shares of the stock. NewEdge Advisors LLC grew its position in Bio-Techne by 15,993.8% in the first quarter. NewEdge Advisors LLC now owns 7,725 shares of the biotechnology company's stock valued at $404,000 after acquiring an additional 7,677 shares in the last quarter. Henshaw Capital LLC increased its stake in Bio-Techne by 31.2% during the 1st quarter. Henshaw Capital LLC now owns 45,905 shares of the biotechnology company's stock worth $2,399,000 after buying an additional 10,915 shares during the period. Summitry LLC lifted its holdings in Bio-Techne by 17.1% in the 1st quarter. Summitry LLC now owns 6,013 shares of the biotechnology company's stock worth $314,000 after buying an additional 879 shares in the last quarter. Intrinsic Edge Capital Management LLC purchased a new position in Bio-Techne in the 1st quarter valued at about $5,749,000. Finally, Edgestream Partners L.P. purchased a new position in Bio-Techne in the 1st quarter valued at about $292,000. 98.95% of the stock is owned by institutional investors and hedge funds.</p>
<div class="lb-trans"><p>幾家對沖基金和其他機構投資者最近買入和賣出了該股票的股份。NewEdge Advisors LLC 在第一季度將其在 Bio-Techne 的持倉增加了 15,993.8%。NewEdge Advisors LLC 目前擁有 7,725 股生物技術公司的股票，價值 404,000 美元，此前在上個季度增持了 7,677 股。Henshaw Capital LLC 在第一季度將其在 Bio-Techne 的股份增加了 31.2%。Henshaw Capital LLC 目前擁有 45,905 股生物技術公司的股票，價值 2,399,000 美元，此前在此期間增持了 10,915 股。Summitry LLC 在第一季度將其在 Bio-Techne 的持倉增加了 17.1%。Summitry LLC 目前擁有 6,013 股生物技術公司的股票，價值 314,000 美元，此前在上個季度增持了 879 股。Intrinsic Edge Capital Management LLC 在第一季度購買了 Bio-Techne 的新頭寸，價值約為 5,749,000 美元。最後，Edgestream Partners L.P.在第一季度購買了 Bio-Techne 的新頭寸，價值約為 292,000 美元。98.95% 的股票由機構投資者和對沖基金持有。</p>
</div><h2>Key Headlines Impacting Bio-Techne</h2>
<div class="lb-trans"><h2>影響 Bio-Techne 的關鍵頭條</h2>
</div><p>Here are the key news stories impacting Bio-Techne this week:</p>
<div class="lb-trans"><p>以下是本週影響 Bio-Techne 的關鍵新聞：</p>
</div><ul>
<li>Positive Sentiment: Merck KGaA agreed to buy Bio-Techne for $73 per share in cash, giving shareholders a clear exit value and likely driving the stock toward the deal price. Merck KGaA, Darmstadt, Germany, Agrees to Acquire Bio-Techne</li>
<li>Positive Sentiment: The offer represents a sizable premium to Bio-Techne’s recent share price, which typically boosts takeover-target stocks as investors price in deal completion. Germany's Merck to buy Bio-Techne for $73 per share</li>
<li>Neutral Sentiment: Multiple law firms announced shareholder investigations into whether Bio-Techne’s board secured a fair price, which could create legal noise but does not change the announced deal terms. Shareholder Alert: Ademi LLP investigates whether Bio-Techne Corporation is obtaining a Fair Price for Public Shareholders</li>
<li>Neutral Sentiment: Reported short-interest data showed no meaningful short position, so the move appears driven more by the takeover announcement than by short covering. Bio-Techne Surges on $73-Per-Share Cash Takeover Agreement</li>
</ul>
<div class="lb-trans"><ul>
<li>積極情緒：默克 KGaA 同意以每股 73 美元的現金收購 Bio-Techne，為股東提供明確的退出價值，並可能推動股票接近交易價格。德國達姆施塔特的默克同意收購 Bio-Techne</li>
<li>積極情緒：該報價相對於 Bio-Techne 最近的股價具有相當大的溢價，通常會提升收購目標股票的價格，因為投資者會考慮交易完成。德國默克以每股 73 美元收購 Bio-Techne</li>
<li>中性情緒：多家律師事務所宣佈對股東進行調查，以確定 Bio-Techne 的董事會是否獲得了公平價格，這可能會產生法律噪音，但不會改變已宣佈的交易條款。股東警報：Ademi LLP 調查 Bio-Techne 公司是否為公眾股東獲得公平價格</li>
<li>中性情緒：報告的空頭頭寸數據顯示沒有顯著的空頭頭寸，因此這一舉動似乎更多是由收購公告驅動，而非空頭回補。Bio-Techne 因每股 73 美元的現金收購協議而激增</li>
</ul>
</div><h2>About Bio-Techne</h2>
<div class="lb-trans"><h2>關於 Bio-Techne</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（獲取免費報告）</p>
</div><p>Bio-Techne Corporation NASDAQ: TECH is a global life sciences company that develops, manufactures and sells high-quality reagents, instruments and services for the research, diagnostic and bioprocessing markets. Its core product offerings include recombinant proteins, antibodies, immunoassays, nucleic acid probes and kits, single-cell analysis solutions and automated protein analysis systems. Flagship brands such as R&amp;D Systems, Novus Biologicals, ProteinSimple and Advanced Cell Diagnostics provide researchers and clinicians with reliable tools for cell biology, immunology, proteomics and genomics applications.</p>
<div class="lb-trans"><p>Bio-Techne Corporation（納斯達克：TECH）是一家全球生命科學公司，開發、製造和銷售高質量的試劑、儀器和服務，面向研究、診斷和生物加工市場。其核心產品包括重組蛋白、抗體、免疫測定、核酸探針和試劑盒、單細胞分析解決方案以及自動化蛋白分析系統。R&amp;D Systems、Novus Biologicals、ProteinSimple 和 Advanced Cell Diagnostics 等旗艦品牌為研究人員和臨牀醫生提供可靠的細胞生物學、免疫學、蛋白質組學和基因組學應用工具。</p>
</div><p>Headquartered in Minneapolis, Minnesota, Bio-Techne serves customers across North America, Europe and the Asia-Pacific region through a combination of direct sales, distributors and strategic partnerships.</p>
<div class="lb-trans"><p>Bio-Techne 總部位於明尼阿波利斯，明尼蘇達州，通過直接銷售、分銷商和戰略合作伙伴關係為北美、歐洲和亞太地區的客户提供服務。</p>
</div><h2>Recommended Stories</h2>
<div class="lb-trans"><h2>推薦故事</h2>
</div><ul>
<li>Five stocks we like better than Bio-Techne</li>
<li>BlackBerry’s Rally Is Running on a Bigger AI Story Than Earnings Alone</li>
<li>MDA Space Targets US Defense Market With $620M Acquisition</li>
<li>Carnival's Second Quarter: Is the Stock Still Complicated?</li>
<li>Domino's Stock Slides to 52-Week Low as Investors Digest CEO Change</li>
</ul>
<div class="lb-trans"><ul>
<li>我們更看好的五隻股票，而不是 Bio-Techne</li>
<li>黑莓的反彈不僅僅依賴於盈利，更是一個更大的人工智能故事</li>
<li>MDA Space 以 6.2 億美元收購目標美國國防市場</li>
<li>嘉年華的第二季度：這隻股票仍然複雜嗎？</li>
<li>多米諾的股票因投資者消化 CEO 更換而跌至 52 周低點</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VEVDSA" alt="" original-src="https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx?Prefix=NASDAQ&amp;Symbol=TECH"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Bio-Techne Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1,000 美元在 Bio-Techne 嗎？</h2>
</div><p>Before you consider Bio-Techne, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮 Bio-Techne 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Bio-Techne wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄建議客户現在購買的股票，而 Bio-Techne 並不在名單上。</p>
</div><p>While Bio-Techne currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Bio-Techne 目前在分析師中獲得了中等買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

Bio-Techne (NASDAQ:TECH) Cut to "Hold" at Leerink Partners

Market Beat

Bio-Techne（NASDAQ:TECH）在 Leerink Partners 被下調至 “持有” 評級